Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of 'β-blockers' in a murine asthma model

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 115-124

  Lin, Rui ^a   Peng, Hui ^b   Nguyen, Long P ^a   Dudekula, Noor B ^a   Shardonofsky, Felix ^c   Knoll, Brian J ^a   Parra, Sergio ^a   Bond, Richard A ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b University of Houston   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Adrenoceptors; blockers; Airway hyperresponsiveness; Asthma; Bronchial relaxation; Forced oscillation technique; Inverse agonists; Mouse trachea; Prostaglandin receptors

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E RECEPTOR;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BRONCHODILATATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; HOMOGENATE; IMMUNOFLUORESCENCE; MALE; MOUSE; MUSCLE TONE; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TECHNIQUE; TRACHEA; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; AIRWAY RESISTANCE; ANIMALS; ASTHMA; BLOTTING, WESTERN; BRONCHIAL PROVOCATION TESTS; DRUG ADMINISTRATION SCHEDULE; FLUORESCENT ANTIBODY TECHNIQUE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METHACHOLINE CHLORIDE; METOPROLOL; MICE; MICE, INBRED BALB C; NADOLOL; OVALBUMIN; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2;

EID: 38049057402     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.06.003     Document Type: Article

References (55)

1. Barnes P.J. Drugs for asthma. Br J Pharmacol 147 Suppl 1 (2006) S297-S303
2. Barnes P.J. Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci 52 26 (1993) 2101-2109
3. Britton J., Hanley S.P., Garrett H.V., Hadfield J.W., and Tattersfield A.E. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax 43 4 (1988) 300-305
4. Rossing T.H., Fanta C.H., Goldstein D.H., Snapper J.R., and McFadden Jr. E.R. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis 122 3 (1980) 365-371
5. Waldeck B. Beta-adrenoceptor agonists and asthma-100 years of development. Eur J Pharmacol 445 1-2 (2002) 1-12
6. FDA. Serevent, advair, foradil withdrawals to be considered by Advisory Committee, 2005, [cited].
7. Spitzer W.O., Suissa S., Ernst P., Horwitz R.I., Habbick B., Cockcroft D., et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326 8 (1992) 501-506
8. Drazen J.M., Israel E., Boushey H.A., Chinchilli V.M., Fahy J.V., Fish J.E., et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 335 12 (1996) 841-847
9. Taylor D.R., Town G.I., Herbison G.P., Boothman-Burrell D., Flannery E.M., Hancox B., et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53 9 (1998) 744-752
10. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 1 (2006) 15-26
11. Suissa S., Ernst P., Boivin J.F., Horwitz R.I., Habbick B., Cockroft D., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149 3 Pt 1 (1994) 604-610
12. Nicholas G., Oakley C., Pouleur H., Rouseeau M.F., Ryden L.E., and Ellens H. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 336 8706 (1990) 1-6
13. Kolar M., Holzmann K., Weber G., Leitner E., and Schwab H. Molecular characterization and functional analysis in Aspergillus nidulans of the 5′-region of the Penicillium chrysogenum isopenicillin N-synthetase gene. J Biotechnol 17 1 (1991) 67-80
14. Dunn T.L., Gerber M.J., Shen A.S., Fernandez E., Iseman M.D., and Cherniack R.M. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis 133 2 (1986) 264-268
15. Nelson W.L., Fraunfelder F.T., Sills J.M., Arrowsmith J.B., and Kuritsky J.N. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 102 5 (1986) 606-611
16. Spitz D.J. An unusual death in an asthmatic patient. Am J Forensic Med Pathol 24 3 (2003) 271-272
17. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., and Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 5 (1995) 1154-1161
18. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334 21 (1996) 1349-1355
19. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., and Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98 12 (1998) 1184-1191
20. Callaerts-Vegh Z., Evans K.L., Dudekula N., Cuba D., Knoll B.J., Callaerts P.F., et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 101 14 (2004) 4948-4953
21. Evans K.L., Bond R.A., Corry D.B., and Shardonofsky F.R. Frequency dependence of respiratory system mechanics during induced constriction in a murine model of asthma. J Appl Physiol 94 1 (2003) 245-252
22. Costall B., Naylor R.J., and Tan C.C. Mechanism of action of apomorphine on rat gastric secretion. Eur J Pharmacol 116 3 (1985) 279-285
23. Kubota T., Yamazaki N., Sudo J., Monma Y., Kaku T., Okuyama T., et al. Protective effects of adrenoceptor-blocking agents on myocardial injury induced by epinephrine in mice. J Toxicol Sci 15 1 (1990) 1-13
24. Fust A., Bates J.H., and Ludwig M.S. Mechanical properties of mouse distal lung: in vivo Versus in vitro comparison. Respir Physiol Neurobiol 143 1 (2004) 77-86
25. Wagers S., Lundblad L.K., Ekman M., Irvin C.G., and Bates J.H. The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?. J Appl Physiol 96 6 (2004) 2019-2027
26. McGraw D.W., Almoosa K.F., Paul R.J., Kobilka B.K., and Liggett S.B. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 112 4 (2003) 619-626
27. Henry P.J., Rigby P.J., and Goldie R.G. Distribution of beta 1- and beta 2-adrenoceptors in mouse trachea and lung: a quantitative autoradiographic study. Br J Pharmacol 99 1 (1990) 136-144
28. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144 3 (2005) 317-322
29. Broadley K.J. Beta-adrenoceptor responses of the airways: for better or worse. Eur J Pharmacol 533 1-3 (2006) 15-27
30. Lefkowitz R.J., Hausdorff W.P., and Caron M.G. Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci 11 5 (1990) 190-194
31. Haney S., and Hancox R.J. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 6 (2005) 107
32. Speizer F.E., Doll R., Heaf P., and Strang L.B. Investigation into use of drugs preceding death from asthma. Br Med J 1 5588 (1968) 339-343
33. Szentivanyi A., Heim O., and Schultze P. Changes in adrenoceptor densities in membranes of lung tissue and lymphocytes from patients with atopic disease. Ann NY Acad Sci 332 (1979) 295-298
34. Szentivanyi A. The conformational flexibility of adrenoceptors and the constitutional basis of atopy. Triangle 18 4 (1979) 109-115
35. Spina D., Rigby P.J., Paterson J.W., and Goldie R.G. Autoradiographic localization of beta-adrenoceptors in asthmatic human lung. Am Rev Respir Dis 140 5 (1989) 1410-1415
36. Gamboa P.M., de la Cuesta C.G., Sanz M.L., Garcia B.E., and Oehling A. Decrease of beta-receptors after the antigen-specific bronchial provocation test in bronchial asthma. Allergol Immunopathol (Madr) 18 3 (1990) 115-119
37. Hataoka I., Okayama M., Sugi M., Inoue H., Takishima T., and Shirato K. Decrease in beta-adrenergic receptors of lymphocytes in spontaneously occurring acute asthma. Chest 104 2 (1993) 508-514
38. Torphy T.J., Zhou H.L., and Cieslinski L.B. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 263 3 (1992) 1195-1205
39. Dent G., White S.R., Tenor H., Bodtke K., Schudt C., Leff A.R., et al. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 11 1 (1998) 47-56
40. Le Jeune I.R., Shepherd M., Van Heeke G., Houslay M.D., and Hall I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 277 39 (2002) 35980-35989
41. Wright L.C., Seybold J., Robichaud A., Adcock I.M., and Barnes P.J. Phosphodiesterase expression in human epithelial cells. Am J Physiol 275 4 Pt 1 (1998) L694-L700
42. Conti M., Richter W., Mehats C., Livera G., Park J.Y., and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278 8 (2003) 5493-5496
43. Giembycz M. PDE4D-deficient mice knock the breath out of asthma. Trends Pharmacol Sci 21 8 (2000) 291-292
44. (i). Circ Res 87 8 (2000) 705-709
45. (i) proteins. Sci STKE 2001 104 (2001) RE15
46. Xiao R.P., Avdonin P., Zhou Y.Y., Cheng H., Akhter S.A., Eschenhagen T., et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84 1 (1999) 43-52
47. Xiao R.P., Ji X., and Lakatta E.G. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47 2 (1995) 322-329
48. Hakonarson H., Herrick D.J., and Grunstein M.M. Mechanism of impaired beta-adrenoceptor responsiveness in atopic sensitized airway smooth muscle. Am J Physiol 269 5 Pt 1 (1995) L645-L652
49. (i3) protein in augmented contraction of bronchial smooth muscle from antigen-induced airway hyperresponsive rats. Biochem Pharmacol 61 7 (2001) 921-924
50. Hall J.A., Kaumann A.J., and Brown M.J. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ Res 66 6 (1990) 1610-1623
51. Kaumann A.J., and Sanders L. 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic beta-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol 349 4 (1994) 331-337
52. Sanders L., Lynham J.A., and Kaumann A.J. Chronic beta 1-adrenoceptor blockade sensitises the H1 and H2 receptor systems in human atrium: role of cyclic nucleotides. Naunyn Schmiedebergs Arch Pharmacol 353 6 (1996) 661-670
53. Berg K.A., Stout B.D., Cropper J.D., Maayani S., and Clarke W.P. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55 5 (1999) 863-872
54. 2 receptor-dependent mechanisms. Biochemistry 44 42 (2005) 13771-13782
55. Lima D.R., and Turner P. Beta-blocking drugs increase responsiveness to prostacyclin in hypertensive patients. Lancet 2 8295 (1982) 444